Atherosclerosis
Volume 183, Issue 2 , Pages 189-198 , December 2005

Clots, kinins and coronaries

Received 31 March 2005 ,Revised 22 May 2005 ,Accepted 26 May 2005.

References 

  1. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–376
  2. Abelous JE, Bardier E. Les substances hypotensives de l’urine humaine normale. CR Sceances Soc Biol. 1909;66:511
  3. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol. 2001;19(429):161–176
  4. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol. 1999;57:1–164
  5. Khairallah PA, Page IH. Effects of bradykinin and angiotensin on smooth muscle. Ann NY Acad Sci. 1963;104:212–221
  6. Labinjoh C, Newby DE, Dawson P, et al. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res. 2000;47:707–714
  7. Benjamin N, Cockcroft JR, Collier JG, et al. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989;412:543–555
  8. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood. 1987;70:1–15
  9. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation. 2000;102:2190–2196
  10. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol. 2002;109:195–209
  11. Schmaier AH. The plasma kallikrein–kinin system counterbalances the rennin–angiotensin system. J Clin Invest. 2002;109:1007–1009
  12. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1–46
  13. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1–80
  14. McCarthy DA, Potter DE, Nicolaides ED. An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. J Pharmacol Exp Ther. 1965;148:117–122
  15. Ferreira SH, Vane JR. Half-lives of peptides and amines in the circulation. Nature. 1967;215:1237–1240
  16. Bonner G, Preis S, Schunk U, Toussaint C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol. 1990;15(Suppl 6):S46–S56
  17. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005;57:27–77
  18. Menke JG, Borkowski JA, Bierilo KK, et al. Expression cloning of a human B1 bradykinin receptor. J Biol Chem. 1994;269:21583–21586
  19. Hess JF, Borkowski JA, Young GS, Strader CD, Ransom RW. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun. 1992;184:260–268
  20. Sardi SP, Ares VR, Errasti AE, Rothlin RP. Bradykinin B1 receptors in human umbilical vein: pharmacological evidence of up-regulation, and induction by interleukin-1 beta. Eur J Pharmacol. 1998;358:221–227
  21. Sardi SP, Daray FM, Errasti AE, et al. Further pharmacological characterization of bradykinin B1 receptor up-regulation in human umbilical vein. J Pharmacol Exp Ther. 1999;290:1019–1025
  22. McLean PG, Perretti M, Ahluwalia A. Kinin B(1) receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res. 2000;48:194–210
  23. McLean PG, Perretti M, Ahluwalia A. Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9-bradykinin-induced coronary vasodilation. Br J Pharmacol. 1999;128:275–282
  24. Tschope C, Heringer-Walther S, Koch M, et al. Upregulation of bradykinin B1-receptor expression after myocardial infarction. Br J Pharmacol. 2000;129:1537–1538
  25. Emanueli C, Bonaria Salis M, Stacca T, et al. Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation. 2002;105:360–366
  26. Raidoo DM, Ramsaroop R, Naidoo S, Muller-Esterl W, Bhoola KD. Kinin receptors in human vascular tissue: their role in atheromatous disease. Immunopharmacology. 1997;36:153–160
  27. Nwator IA, Whalley ET. Angiotensin converting enzyme inhibitors and expression of des-Arg9-BK (kinin B1) receptors in vivo. Eur J Pharmacol. 1989;160:125–132
  28. Marin-Castano ME, Schanstra JP, Neau E, et al. Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 2002;105:627–632
  29. Toda N, Okamura T. Endothelium-dependent and -independent responses to vasoactive substances of isolated human coronary arteries. Am J Physiol. 1989;257:H988–H995
  30. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost. 1997;77:522–525
  31. Cockcroft JR, Chowienczyk PJ, Brett SE, Bender N, Ritter JM. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol. 1994;38:317–321
  32. Kuga T, Mohri M, Egashira K, et al. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol. 1997;30:108–112
  33. Kato M, Shiode N, Yamagata T, Matsuura H, Kajiyama G. Bradykinin induced dilatation of human epicardial and resistance coronary arteries in vivo: effect of inhibition of nitric oxide synthesis. Heart. 1997;78:493–498
  34. Kuga T, Egashira K, Mohri M, et al. Bradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivo. Circulation. 1995;92:183–189
  35. Davie AP, Dargie HJ, McMurray JJ. Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation. 1999;100:268–273
  36. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation. 2001;104:2177–2181
  37. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95:1115–1118
  38. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285–1292
  39. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424–3430
  40. Astedt B. No crossreaction between circulating plasminogen activator and urokinase. Thromb Res. 1979;14:535–539
  41. Kok P. Separation of plasminogen activators from human plasma and a comparison with activators from human uterine tissue and urine. Thromb Haemost. 1979;41:734–744
  42. Eijnden-Schrauwen Y, Kooistra T, de Vries RE, Emeis JJ. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood. 1995;85:3510–3517
  43. Emeis JJ, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions Suppl. 1992;38:285–291
  44. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985;66:835–839
  45. Chandler WL, Veith RC, Fellingham GW, et al. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J Am Coll Cardiol. 1992;19:1412–1420
  46. Newby DE, Wright RA, Ludlam CA, et al. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997;78:1242–1248
  47. Labinjoh C, Newby DE, Pellegrini MP, et al. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 2001;38:1402–1408
  48. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension. 1999;33:1431–1435
  49. Minai K, Matsumoto T, Horie H, et al. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2001;37:1565–1570
  50. Cruden NL, Tse GH, Ludlam CA, et al. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure. Arterioscler Thromb Vasc Biol. 2005;25:772–777
  51. Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44:913–918
  52. Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol. 2001;280:H2470–H2477
  53. Dwivedi R, Saha S, Chowienczyk PJ, Ritter JM. Block of inward rectifying K+ channels (KIR) inhibits bradykinin-induced vasodilatation in human forearm resistance vasculature. Arterioscler Thromb Vasc Biol. 2005;25:e7–e9
  54. Inokuchi K, Hirooka Y, Shimokawa H, et al. Role of endothelium-derived hyperpolarizing factor in human forearm circulation. Hypertension. 2003;42:919–924
  55. Honing ML, Smits P, Morrison PJ, Rabelink TJ. Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Hypertension. 2000;35:1314–1318
  56. Powers ER, Bannerman KS, Stone J, et al. The effect of captopril on renal, coronary, and systemic hemodynamics in patients with severe congestive heart failure. Am Heart J. 1982;104:1203–1210
  57. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol. 2000;35:60–66
  58. Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 2001;103:799–805
  59. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol. 1994;24:67–73
  60. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 2003;107:579–585
  61. Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol. 2004;24:1043–1048
  62. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci. 1994;87:567–574
  63. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol. 1993;22:579–584
  64. Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol. 2002;40:961–966
  65. Matsumoto T, Minai K, Horie H, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol. 2003;41:1373–1379
  66. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–1346
  67. Brown NJ, Blais C, Gandhi SK, Adam A. ACE insertion/deletion genotype affects bradykinin metabolism. J Cardiovasc Pharmacol. 1998;32:373–377
  68. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation. 2000;102:829–832
  69. Schunkert H. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease. J Mol Med. 1997;75:867–875
  70. Gainer JV, Stein CM, Neal T, Vaughan DE, Brown NJ. Interactive effect of ethnicity and ACE insertion/deletion polymorphism on vascular reactivity. Hypertension. 2001;37:46–51
  71. van Dijk MA, Kroon I, Kamper AM, et al. The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm. J Cardiovasc Pharmacol. 2000;35:484–490
  72. Ohira N, Matsumoto T, Tamaki S, et al. Angiotensin-converting enzyme insertion/deletion polymorphism modulates coronary release of tissue plasminogen activator in response to bradykinin. Hypertens Res. 2004;27:39–45
  73. Bao G, Gohlke P, Qadri F, Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension. 1992;20:74–79
  74. Marcic B, Deddish PA, Jackman HL, Erdos EG. Enhancement of bradykinin and resensitization of its B2 receptor. Hypertension. 1999;33:835–843
  75. Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation. 1997;96:442–447
  76. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 1999;34:285–290
  77. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension. 2002;40:859–865
  78. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995–1001
  79. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000;58:251–259
  80. Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969–1973
  81. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925–935
  82. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation. 2005;111:315–320
  83. Hornig B, Kohler C, Schlink D, Tatge H, Drexler H. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism. Hypertension. 2003;41:1092–1095
  84. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res. 1999;84:695–703
  85. Huang CD, Tliba O, Panettieri RA, Amrani Y. Bradykinin induces interleukin-6 production in human airway smooth muscle cells: modulation by Th2 cytokines and dexamethasone. Am J Respir Cell Mol Biol. 2003;28:330–338
  86. Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34:2068–2071
  87. Brull DJ, Sanders J, Rumley A, et al. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart. 2002;87:252–255
  88. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart. 1999;82:265–268
  89. Christie PD, Edelberg JM, Picard MH, et al. A murine model of myocardial microvascular thrombosis. J Clin Invest. 1999;104:533–539
  90. Xiao Q, Danton MJ, Witte DP, et al. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci. 1997;94:10335–10340
  91. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555–1564
  92. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076–1079
  93. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation. 1993;88:2030–2034
  94. Newby DE, McLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation. 2001;103:1936–1941
  95. Newby DE, Wright RA, Labinjoh C, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation. 1999;99:1411–1415
  96. Pretorius M, Rosenbaum DA, Lefebvre J, Vaughan DE, Brown NJ. Smoking impairs bradykinin-stimulated t-PA release. Hypertension. 2002;39:767–771
  97. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein–kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation. 1995;91:2520–2527
  98. Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 1992;120:129–139
  99. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153
  100. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788
  101. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575–1581
  102. Kennon S, Barakat K, Hitman GA, et al. Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2001;38:724–728
  103. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87–146
  104. Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol. 2001;37:359–366
  105. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation. 2002;106:920–926
  106. Sheikh IA, Kaplan AP. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. Biochem Pharmacol. 1989;38:993–1000
  107. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem. 2003;278:51059–51067
  108. Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res. 2001;101:329–354
  109. Chang JY, Li L, Canals F, Aviles FX. The unfolding pathway and conformational stability of potato carboxypeptidase inhibitor. J Biol Chem. 2000;275:14205–14211
  110. Suzuki K, Muto Y, Fushihara K, et al. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther. 2004;309:607–615
  111. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. 1995;96:2534–2538
  112. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation. 1996;93:1328–1330
  113. Cruden NL, Edwardson L, Lawes L, et al. Potentiation of fibrinolysis by inhibition of thrombin activatable fibrinolysis inhibitor in whole human blood. Br J Haematol. 2004;25(s1):43;[abstract]
  114. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693–1697
  115. Armstrong PW, Lorell BH, Nissen S, Borer J. Circulation. 2002;106:e9011–e9012

PII: S0021-9150(05)00359-X

doi: 10.1016/j.atherosclerosis.2005.05.038

Atherosclerosis
Volume 183, Issue 2 , Pages 189-198 , December 2005

Article Tools

* Image Usage & Resolution